Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

Actinium Pharmaceuticals, Inc. (ATNM)

Total paid for Promotions this month: $0
E-mails this Month: 1
Estimated Volume Generated: $0
Research Report on ATNM: Click to see
* The information presented is based on information for May , 2016
Hi, New Trade Alert: Actinium Pharmaceuticals, Inc. [ NYSE: ATNM ]  Highlights: Last Close: $3.01 | Yahoo Finance Quote Key level to watch on present momentum is 4.35.   ATNM has rallied 68% from 2.57 on May 20 to as high as 4.34 on May 26. May 26th (just a few days ago) witnessed upwards of 43% in intraday gains. This showcases massive historical upside opportunity. ATNM consolidated after its huge ...read more
Promoter: AwesomeStocks.com Paying Party: SmallCapSpecialist LLC
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM $30,000 4,128,443
Max Profit: 1.29 % Gain at close: -3.55 %
  View this email in your browser Good morning everyone, Our own Small-Cap oracle has identified this potentially undervalued biotech play. Actinium Pharmaceuticals Inc. (NYSE-MKT: ATNM) “There are three targeted therapies for attacking cancerous cells in the human body: alpha-emitters, beta-emitters, and toxins. The company competes with one other ...read more
Promoter: First Penny Picks Paying Party: Edge Media LLC
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM $60,000 1,667,116
Max Profit: 6.25 % Gain at close: -5.94 %
  View this email in your browser Good morning everyone, Our own Small-Cap oracle has identified this potentially undervalued biotech play. Actinium Pharmaceuticals Inc. (NYSE-MKT: ATNM) “There are three targeted therapies for attacking cancerous cells in the human body: alpha-emitters, beta-emitters, and toxins. The company competes with one other ...read more
Promoter: Stocks Impossible Paying Party: Edge Media LLC
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM $60,000 1,667,116
Max Profit: 6.25 % Gain at close: -5.94 %
  View this email in your browser Good morning everyone, Our own Small-Cap oracle has identified this potentially undervalued biotech play. Actinium Pharmaceuticals Inc. (NYSE-MKT: ATNM) “There are three targeted therapies for attacking cancerous cells in the human body: alpha-emitters, beta-emitters, and toxins. The company competes with one other ...read more
Promoter: Otcbb Journal Paying Party: Edge Media LLC
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM $60,000 1,667,116
Max Profit: 6.25 % Gain at close: -5.94 %
  View this email in your browser Good morning everyone, Our own Small-Cap oracle has identified this potentially undervalued biotech play. Actinium Pharmaceuticals Inc. (NYSE-MKT: ATNM) “There are three targeted therapies for attacking cancerous cells in the human body: alpha-emitters, beta-emitters, and toxins. The company competes with one other ...read more
Promoter: Street Picks Paying Party: Edge Media LLC
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM $60,000 1,667,116
Max Profit: 6.25 % Gain at close: -5.94 %

***** ATNM ***** Mar 16, 2015 21:40

  (Mailing list information, including unsubscription instructions, is located at the end of this message.)   Actinium Pharmaceuticals, Inc. is a biopharmaceutical company with a proprietary platform that combines the precision targeting of monoclonal antibodies with the killing power of alpha and beta radioisotopes, the former being the most potent cancer killing agents in existence. Leveraging this platform and its ties with leading ...read more
Promoter: Pennybuster.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM No compensation UNKNOWN
Max Profit: 18.77 % Gain at close: 16.09 %
  Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 Months in Elderly Secondary Acute Myeloid Leukemia If you cannot read this email, click here   Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 Months in Elderly Secondary Acute Myeloid Leukemia NEW YORK, NY--(Marketwired - November 06, 2014) - Significant ...read more
Promoter: RedChip Companies, Inc. Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM Unknown compensation UNKNOWN
Max Profit: 2.60 % Gain at close: Pending
  MissionIR Inside Track: Actinium Pharmaceuticals, Inc. (ATNM) In a 6-minute interview at the 6th Annual LD Micro Conference in Bel Air, CA, Kaushik Dave, Ph.D., President & CEO of Actinium Pharmaceuticals, Inc.provided an overview of the company, recent accomplishments, and its outlook including the potential and key milestones expected for its two lead compounds: Iomab(TM)-B and Actimab-A. Key Investment Highlights Breakthrough ...read more
Promoter: MissionIR Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM $50,000 UNKNOWN
Max Profit: 4.52 % Gain at close: Pending
  Actinium Pharmaceuticals, Inc. (ATNM) Actinium Pharmaceuticals is a biopharmaceutical company with a proprietary platform that combines the precision targeting of monoclonal antibodies with the killing power of alpha and beta radioisotopes, the former being the most potent cancer killing agents in existence. View The Full Company Profile   ATNM: MIR, an affiliate of DreamTeamGroup, will receive $50,000 from ATNM for 150 days ...read more
Promoter: Tip.us Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
ATNM $50,000 UNKNOWN
Max Profit: 3.70 % Gain at close: Pending
First  << Last